C反应蛋白、乳酸脱氢酶和β_(2)-微球蛋白检测对急性白血病患者治疗预后评估中的价值

The Value of C-reactive Protein,Lactate Dehydrogenase andβ_(2)-microglobulin Assays in the Prognostic Assessment of the Treatment of Patients with Acute Leukemia

目的探讨C反应蛋白(C-reactiveprotein,CRP)、乳酸脱氢酶(lactate dehydrogenase,LDH)和β_(2)-微球蛋白(beta-2-microglobulin,β_(2)-MG)检测对急性白血病患者治疗预后评估中的价值。方法选取2018年8月—2021年8月江苏省人民医院浦口分院收治的76例急性白血病患者,设定为观察组,并选取同时期健康体检者76名,设定为对照组。比较两组CRP、LDH和β_(2)-MG水平及预后情况。结果观察组患者CRP(76.13±5.06)mg/L、LDH(586.74±13.58)U/L、β_(2)-MG(3.81±0.25)mg/L水平明显高于对照组,差异有统计学意义(t=126.793、202.249、87.016,P<0.05);观察组ANLL患者血清CRP、LDH、β_(2)-MG水平高于ALL患者,差异有统计学意义(P<0.05);相比较初治组,缓解组CRP(2.89±0.11)mg/L、LDH(158.54±11.69)U/L、β_(2)-MG(1.29±0.11)mg/L明显降低,差异有统计学意义(t=116.611、198.872、75.247,P<0.05);与未缓解组(74.85±5.65)mg/L、(579.75±12.55)U/L、(3.68±0.23)mg/L相比较,缓解组CRP、LDH、β_(2)-MG水平显著降低,差异有统计学意义(t=106.140、109.396、55.236,P<0.05);未缓解组血清CRP、LDH、β_(2)-MG水平与初治组相比较,差异无统计学意义(P>0.05);观察组患者治疗后,65例缓解,11例病情未缓解,患者均无严重不良反应。结论CRP、LDH和β_(2)-MG对急性白血病患者具有明显检测作用,可对治疗预后进行合理评估,应用价值高。

Objective To investigate the value of C-reactive protein(CRP),lactate dehydrogenase(LDH)andβ_(2)-microglobulin(β_(2)-MG)assays in the prognostic assessment of treatment of patients with acute leukemia.Methods Seventy-six acute leukemia patients admitted to the Pukou branch of Jiangsu Provincial People′s Hospital from August 2018 to August 2021 were selected and set as the observation group,and 76 healthy check-ups from the same period were selected and set as the control group.The levels of CRP,LDH andβ_(2)-MG and the prognosis of the two groups were compared.Results The levels of CRP(76.13±5.06)mg/L,LDH(586.74±13.58)U/L andβ_(2)-MG(3.81±0.25)mg/L were significantly higher in the observation group than in the control group,and the difference was statistically significant(t=126.793,202.249,87.016,P<0.05).The serum CRP,LDH,andβ_(2)-MG levels of ANLL patients in the observation group were higher than those of ALL patients,and the differences were statistically significant(P<0.05).Compared to the primary treatment group,CRP(2.89±0.11)mg/L,LDH(158.54±11.69)U/L,andβ_(2)-MG(1.29±0.11)mg/L were significantly lower in the remission group,with statistically significant differences(t=116.611,198.872,75.247,P<0.05).The levels of CRP,LDH,andβ_(2)-MG were significantly lower in the remission group compared with(74.85±5.65)mg/L,(579.75±12.55)U/L,and(3.68±0.23)mg/L in the unremitted group,and the differences were statistically significant(t=106.140,109.396,55.236,P<0.05).There was no statistically significant difference in serum CRP,LDH,andβ_(2)-MG levels in the unremitting group compared with the primary treatment group(P>0.05).After treatment,65 patients in the observation group were in remission and 11 patients were not in remission,and none of the patients had serious adverse reactions.Conclusion CRP,LDH andβ_(2)-MG have significant detectable effects on patients with acute leukemia,and can be reasonably evaluated for treatment prognosis,with high application value.